Cita APA

Habib, A., Sacconi, S., Cortés-Vicente, E., Mahuwala, Z., Mantegazza, R., Vissing, J., . . . Woltering, F. (2024). Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis.

Citación estilo Chicago

Habib, A.A., et al. Efficacy and Safety of Rozanolixizumab in Patients With Muscle-specific Tyrosine Kinase Autoantibody-positive Generalised Myasthenia Gravis. 2024.

Cita MLA

Habib, A.A., et al. Efficacy and Safety of Rozanolixizumab in Patients With Muscle-specific Tyrosine Kinase Autoantibody-positive Generalised Myasthenia Gravis. 2024.